1.A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
Hyung Joon KIM ; Ju Hyun KIM ; Jong Eun YEON ; Yeon Seok SEO ; Jeong Won JANG ; Yong Kyun CHO ; Byoung Kuk JANG ; Byung Hoon HAN ; Changhyeong LEE ; Joon Hyeok LEE ; Jung-Hwan YOON ; Kang Mo KIM ; Moon Young KIM ; Do Young KIM ; Neung Hwa PARK ; Eun Young CHO ; June Sung LEE ; Jin-Woo LEE ; In Hee KIM ; Byung-Cheol SONG ; Byung-Seok LEE ; Oh Sang KWON
Journal of Korean Medical Science 2022;37(11):e92-
Background:
Tenofovir disoproxil fumarate (TDF, Viread® ) had been used as a standard treatment option of chronic hepatitis B (CHB). This clinical trial was conducted to evaluate the efficacy and safety of DA-2802 (tenofovir disoproxil orotate) compared to TDF.
Methods:
The present study was a double blind randomized controlled trial. Patients with CHB were recruited from 25 hospitals in Korea and given DA-2802 at a dose of 319 mg once daily or Viread® at a dose of 300 mg once daily for 48 weeks from March 2017 to January 2019. Change in hepatitis B virus (HBV) DNA level at week 48 after dosing compared to baseline was the primary efficacy endpoint. Secondary efficacy endpoints were proportions of subjects with undetectable HBV DNA, those with normal alanine aminotransferase (ALT) levels, and those with loss of hepatitis B envelop antigen (HBeAg), those with loss of hepatitis B surface antigen (HBsAg). Adverse events (AEs) were also investigated.
Results:
A total of 122 patients (DA-2802 group: n = 61, Viread® group: n = 61) were used as full analysis set for efficacy analysis. Mean age, proportion of males, laboratory results and virologic characteristics were not different between the two groups. The change in HBV DNA level at week 48 from baseline was −5.13 ± 1.40 in the DA-2802 group and −4.97 ± 1.40 log 10 copies/mL in the Viread® group. The analysis of primary endpoint using the nonparametric analysis of covariance showed statistically significant results (P < 0.001), which confirmed non-inferiority of DA-2802 to Viread® by a prespecified noninferiority margin of 1. The proportion of undetectable HBV DNA was 78.7% in the DA-2802 group and 75.4% in the Viread® group (P = 0.698). The proportion of subjects who had normal ALT levels was 75.4% in the DA-2802 group and 73.3% in the Viread® group (P = 0.795). The proportion of those with HBeAg loss was 8.1% in the DA-2802 group and 10.8% in the Viread® group (P = 1.000). No subject showed HBsAg loss. The frequency of AEs during treatment was similar between the two groups. Most AEs were mild to moderate in severity.
Conclusion
DA-2802 is considered an effective and safe treatment for patients with CHB.
2.Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Byoung Soo KWON ; Ji Hyun PARK ; Woo Sung KIM ; Joon Seon SONG ; Chang Min CHOI ; Jin Kyung RHO ; Jae Cheol LEE
Tuberculosis and Respiratory Diseases 2017;80(2):187-193
BACKGROUND: Third-generation tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) have proved efficacious in treating non-small cell lung cancer (NSCLC) patients with acquired resistance resulting from the T790M mutation. However, since almost 50% patients with the acquired resistance do not harbor the T790M mutation, retreatment with first- or second-generation EGFR-TKIs may be a more viable therapeutic option. Here, we identified positive response predictors to retreatment, in patients who switched to a different EGFR-TKI, following initial treatment failure. METHODS: This study retrospectively reviewed the medical records of 42 NSCLC patients with EGFR mutations, whose cancers had progressed following initial treatment with gefitinib or erlotinib, and who had switched to a different first-generation EGFR-TKI during subsequent retreatment. To identify high response rate predictors in the changed EGFR-TKI retreatment, we analyzed the relationship between clinical and demographic parameters, and positive clinical outcomes, following retreatment with EGFR-TKI. RESULTS: Overall, 30 (71.4%) patients received gefitinib and 12 (28.6%) patients received erlotinib as their first EGFR-TKI treatment. Following retreatment with a different EGFR-TKI, the overall response and disease control rates were 21.4% and 64.3%, respectively. There was no significant association between their overall responses. The median progression-free survival (PFS) after retreatment was 2.0 months. However, PFS was significantly longer in patients whose time to progression was ≥10 months following initial EGFR-TKI treatment, who had a mutation of exon 19, or whose treatment interval was <90 days. CONCLUSION: In patients with acquired resistance to initial EGFR-TKI therapy, switched EGFR-TKI retreatment may be a salvage therapy for individuals possessing positive retreatment response predictors.
Carcinoma, Non-Small-Cell Lung*
;
Disease-Free Survival
;
Erlotinib Hydrochloride
;
Exons
;
Humans
;
Medical Records
;
Protein-Tyrosine Kinases
;
Receptor, Epidermal Growth Factor
;
Retreatment*
;
Retrospective Studies
;
Salvage Therapy
;
Treatment Failure
3.Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.
Hye Young JWA ; Yoo Kyung CHO ; Eun Kwang CHOI ; Heung Up KIM ; Hyun Joo SONG ; Soo Young NA ; Sun Jin BOO ; Seung Uk JEONG ; Bong Soo KIM ; Byoung Wook LEE ; Byung Cheol SONG
Clinical and Molecular Hepatology 2016;22(1):183-187
Recent studies suggest that liver cirrhosis is reversible after administering oral nucleos(t)ide analogue therapy to patients with hepatitis B virus (HBV) infection. However, few studies have addressed whether esophageal varices can regress after such therapy. We report a case of complete regression of esophageal varices during entecavir therapy in patients with HBV-related liver cirrhosis, suggesting that complications of liver cirrhosis such as esophageal varices can regress after the long-term suppression of HBV replication.
Abdomen/diagnostic imaging
;
Antiviral Agents/*therapeutic use
;
DNA, Viral/blood
;
Esophageal and Gastric Varices/complications/prevention & control
;
Guanine/*analogs & derivatives/therapeutic use
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/complications/*drug therapy/virology
;
Humans
;
Liver Cirrhosis/*diagnosis/etiology
;
Male
;
Middle Aged
;
Polymerase Chain Reaction
;
Ultrasonography
4.Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K).
Se Hyun NAM ; Hyun Jin CHOI ; Woo Dae KANG ; Seok Mo KIM ; Myong Cheol LIM ; Sang Yoon PARK ; Jung Sup KIM ; Byoung Gie KIM ; Duk Soo BAE ; Jeong won LEE ; Tae Joong KIM ; Taejong SONG
Journal of Korean Medical Science 2016;31(12):1969-1975
Given the growing number of cancer patients and the resulting increase in the administration of chemotherapeutic agents, convenient and effective methods for measuring the symptoms and quality of life associated with the hand-foot syndrome (HFS) are needed. Therefore, the aim of this study was to develop and validate the Korean version of the hand-foot skin reaction and quality of life questionnaire (HF-QoL-K), comprising a 20-item symptom domain and an 18-item daily activity domain. After we developed the HF-QoL-K, 209 Korean patients with gynecologic cancer who were undergoing chemotherapeutic agents relating the HFS were asked to fill in the questionnaire. The content validity, internal consistency reliability, and test-retest reliability were evaluated. The internal validity index, Cronbach’s alpha coefficient, and intra-class correlation coefficient of the HF-QoL-K were 0.90, 0.958, and 0.825 (95% confidence interval [CI], 0.774–0.865), respectively. The scatter plot (Pearson correlation coefficient, 0.826) and the Bland-Altman plot for test-retest reliability were also acceptable. The HF-QoL-K instrument is a valid and reliable questionnaire for the measurement of the symptoms and quality of life in Korean cancer patients suffering HFS.
Drug Therapy
;
Hand-Foot Syndrome
;
Humans
;
Quality of Life*
;
Reproducibility of Results
;
Skin*
5.Prenatal Particulate Matter/Tobacco Smoke Increases Infants' Respiratory Infections: COCOA Study.
Song I YANG ; Byoung Ju KIM ; So Yeon LEE ; Hyo Bin KIM ; Cheol Min LEE ; Jinho YU ; Mi Jin KANG ; Ho Sung YU ; Eun LEE ; Young Ho JUNG ; Hyung Young KIM ; Ju Hee SEO ; Ji Won KWON ; Dae Jin SONG ; Gwangcheon JANG ; Woo Kyung KIM ; Jung Yeon SHIM ; Soo Young LEE ; Hyeon Jong YANG ; Dong In SUH ; Seo Ah HONG ; Kil Yong CHOI ; Youn Ho SHIN ; Kangmo AHN ; Kyung Won KIM ; Eun Jin KIM ; Soo Jong HONG
Allergy, Asthma & Immunology Research 2015;7(6):573-582
PURPOSE: To investigate whether prenatal exposure to indoor fine particulate matter (PM2.5) and environmental tobacco smoke (ETS) affects susceptibility to respiratory tract infections (RTIs) in infancy, to compare their effects between prenatal and postnatal exposure, and to determine whether genetic factors modify these environmental effects. METHODS: The study population consisted of 307 birth cohort infants. A diagnosis of RTIs was based on parental report of a physician's diagnosis. Indoor PM2.5 and ETS levels were measured during pregnancy and infancy. TaqMan was used for genotyping of nuclear factor erythroid 2-related factor (Nrf2) (rs6726395), glutathione-S-transferase-pi (GSTP) 1 (rs1695), and glutathione-S-transferase-mu (GSTM) 1. Microarrays were used for genome-wide methylation analysis. RESULTS: Prenatal exposure to indoor PM2.5 increased the susceptibility of lower RTIs (LRTIs) in infancy (adjusted odds ratio [aOR]=2.11). In terms of combined exposure to both indoor PM2.5 and ETS, prenatal exposure to both pollutants increased susceptibility to LRTIs (aOR=6.56); however, this association was not found for postnatal exposure. The Nrf2 GG (aOR=23.69), GSTM1 null (aOR=8.18), and GSTP1 AG or GG (aOR=7.37) genotypes increased the combined LRTIs-promoting effects of prenatal exposure to the 2 indoor pollutants. Such effects of prenatal indoor PM2.5 and ETS exposure were not found for upper RTIs. CONCLUSIONS: Prenatal exposure to both indoor PM2.5 and ETS may increase susceptibility to LRTIs. This effect can be modified by polymorphisms in reactive oxygen species-related genes.
Cacao*
;
Cohort Studies
;
Diagnosis
;
Genotype
;
Humans
;
Infant
;
Methylation
;
Odds Ratio
;
Oxygen
;
Parents
;
Particulate Matter
;
Parturition
;
Pregnancy
;
Respiratory Tract Infections*
;
Smoke*
;
Tobacco
6.Effect of Pressurized Cement Insertion on Cardiopulmonary Parameters during Cemented Hip Hemiarthroplasty: A Randomized Prospective Study.
Woo Suk SONG ; Joon Cheol CHOI ; Tae Hyun KIM ; Sang Hoon OH ; Sub Ri PARK ; Byoung Hark PARK
Hip & Pelvis 2014;26(4):243-249
PURPOSE: We aimed to investigate the cardiopulmonary effects of pressurized cement insertion in elderly patients undergoing cemented hip hemiarthroplasty. MATERIALS AND METHODS: We conducted a randomized prospective study on elderly patients undergoing cemented hip hemiarthroplasty. Patients were divided into pressurized and non-pressurized groups based on the pressure application during cement insertion. We measured mean arterial blood pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), arterial blood gases and serotonin concentration in blood. These variables were measured before bone cement insertion, and 3 and 5 minute after insertion. They were also measured immediately and 15 minutes after reduction. RESULTS: In cemented hip hemiarthroplasty, there were no significant change in MAP (P=0.92), SBP (P=0.85), DBP (P=0.98), HR (P=0.97) and serotonin concentration over time. There were no statistically significant difference between the two groups in MAP, SBP, DBP, HR, PO2, PaCO2, SaO2 and serotonin concentration, though three minutes after cement insertion, both groups showed decreases in SBP, DBP and MBP. CONCLUSION: The pressurization method in cemented hip hemiarthroplasty was not found to be related with development of bone cement syndromes in elderly patients.
Aged
;
Arterial Pressure
;
Blood Pressure
;
Gases
;
Heart Rate
;
Hemiarthroplasty*
;
Hip*
;
Humans
;
Prospective Studies*
;
Serotonin
7.Efficacy of Hemocontrol Biofeedback System in Intradialytic Hypotension-Prone Hemodialysis Patients.
Hyo Wook GIL ; Kitae BANG ; So Young LEE ; Byoung Geun HAN ; Jin Kuk KIM ; Young Ok KIM ; Ho Cheol SONG ; Young Joo KWON ; Yong Soo KIM
Journal of Korean Medical Science 2014;29(6):805-810
We conducted a study to determine whether the hemocontrol biofeedback system (HBS) can improve intradialytic hypotension (IDH) in hypotension-prone hemodialysis (HD) patients compared with conventional HD. In this multicenter prospective crossover study, 60 hypotension-prone patients were serially treated by conventional HD for 8 weeks (period A), by HD with hemoscan blood volume monitoring for 2 weeks (period B0), and by HBS HD for 8 weeks (period B1). The number of sessions complicated by symptomatic IDH during 24 HD sessions (14.9+/-5.8 sessions, 62.1% in period A vs 9.2+/-7.2 sessions, 38.4% in period B1, P<0.001) and the number of IDH-related nursing interventions in a session (0.96+/-0.66 in period A vs 0.56+/-0.54 in period B1, P<0.001) significantly decreased in period B1 than in period A. Recovery time from fatigue after dialysis was significantly shorter in period B1 than in period A. The patients with higher post-dialysis blood pressure, lower difference between pre- and post-dialysis blood pressure, less frequent IDH, and higher pre- and post-dialysis body weight in period A responded better to HBS in period B1 in regard to the reduction of IDH. In conclusion, HBS may improve the patient tolerability to HD by reducing the IDH frequency and promoting faster recovery from fatigue after dialysis.
Adolescent
;
Adult
;
Aged
;
*Biofeedback, Psychology
;
Blood Pressure
;
Blood Volume
;
Body Weight
;
Cross-Over Studies
;
Fatigue
;
Female
;
Humans
;
Hypotension/etiology/*prevention & control
;
Kidney Failure, Chronic/*therapy
;
Male
;
Middle Aged
;
Prone Position
;
Prospective Studies
;
Renal Dialysis/adverse effects
;
Young Adult
8.Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.
Jae Kwan LEE ; Jin Hwa HONG ; Sokbom KANG ; Dae Yeon KIM ; Byoung Gie KIM ; Sung Hoon KIM ; Yong Man KIM ; Jae Weon KIM ; Jae Hoon KIM ; Tae Jin KIM ; Hyun Jung KIM ; Hye Sun KIM ; Hee Sug RYU ; Jae Yun SONG ; Hyeong Sik AHN ; Chong Woo YOO ; Hye Kyoung YOON ; Keun Ho LEE ; Ahwon LEE ; Yonghee LEE ; In Ho LEE ; Jeong Won LEE ; Taek Sang LEE ; Myong Cheol LIM ; Suk Joon CHANG ; Hyun Hoon CHUNG ; Woong JU ; Hee Jae JOO ; Soo Young HUR ; Sung Ran HONG ; Joo Hyun NAM
Journal of Gynecologic Oncology 2013;24(2):186-203
The consensus guideline development committee of Korean Society of Gynecologic Oncology was reconvened in March 2012. The committee consisted of 36 experts representing 12 university hospitals and professional organizations. The objective of this committee was to develop standardized guidelines for cervical cancer screening tests for Korean women and to distribute these guidelines to every clinician, eventually improving the quality of medical care. Since the establishment of the consensus guideline development committee, evidence-based guidelines have either been developed de novo considering specific Korean situations or by adaptation of preexisting consensus guidelines from other countries. Recommendations for cervical cancer screening tests, management of atypical squamous and glandular cells, and management of low-grade and high-grade squamous intraepithelial lesions were developed. Additionally, recommendations for human papillomavirus DNA testing and recommendations for adolescent and pregnant women with abnormal cervical screening test results were also included.
Adolescent
;
Consensus
;
DNA
;
Female
;
Hospitals, University
;
Humans
;
Mass Screening
;
Pregnant Women
;
Societies
;
Uterine Cervical Neoplasms
9.The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry.
Byoung Hwan LEE ; Nayoung KIM ; Hye Seung LEE ; Jung Mook KANG ; Hyun Kyung PARK ; Hyun Jun JO ; Cheol Min SHIN ; Sang Hyub LEE ; Young Soo PARK ; Jin Hyeok HWANG ; Jin Wook KIM ; Sook Hyang JEONG ; Dong Ho LEE ; Hyun Chae JUNG ; In Sung SONG
Gut and Liver 2012;6(1):71-77
BACKGROUND/AIMS: Intestinal metaplasia (IM) has been regarded as a premalignant condition. This study evaluated the role of the transforming factor CDX2 according to the severity and type of IM. METHODS: This analysis was performed on 383 subjects with IM in the antrum and/or body, with diagnoses that were categorized as controls, dysplasias, and gastric cancers. The IM grades were classified into four groups as negative, mild, moderate or severe using the updated Sydney scoring system. The IM subtypes were categorized as type I, type II, and type III using high iron diamine and alcian blue (pH 2.5) staining. The CDX2 expression in the IM foci was evaluated using immunohistochemistry in specimens from the antrum and/or body. RESULTS: CDX2 expression increased according to IM severity (p=0.001) but was not associated with the IM subtype (p=0.881) in the antrum specimens. Similarly, CDX2 expression increased according to the IM grade (p=0.001) but was not associated with the IM subtype (p=0.755) in the body specimens. CDX2 expression was also increased according to baseline disease in the antrum, especially dysplastic and GC group (p=0.003), but not in the body (p=0.582). However, status of Helicobacter pylori infection was not associated with CDX2 expression in the antrum (p=0.692) and body (p=0.271). CONCLUSIONS: These results show that CDX2 expression is associated with the IM grade regardless of the IM subtype and that it was more frequent in the dysplasia group. These results suggest that CDX2 expression might play an important role in the progression of IM in various environments that can affect neoplastic change.
Alcian Blue
;
Helicobacter pylori
;
Immunohistochemistry
;
Iron
;
Metaplasia
;
Stomach Neoplasms
10.Achilles Tendon Rupture Associated with Ipsilateral Bimalleolar Fracture: A Case Report.
Hyung Jin CHUNG ; Su Young BAE ; Byoung Kwon MIN ; Min Cheol SONG
Journal of Korean Foot and Ankle Society 2011;15(2):107-109
We report here on a case of Achilles tendon rupture associated with ipsilateral bimalleolar fracture that was caused by ski injury. The association of an ankle fracture with rupture of the Achilles tendon is even more infrequent, although both injuries alone are extremely common. We treated as a operation of Achilles tendon repair with Krackow method and open reduction with Tension-band wiring technique for bimalleolar fracture.
Achilles Tendon
;
Animals
;
Ankle
;
Rupture

Result Analysis
Print
Save
E-mail